Open Call: Advancing New Mechanisms and Emerging Treatments in mCRPC
Section
The Pfizer is inviting applications for its competitive grant program focused on enhancing medical education related to emerging treatments in metastatic castration-resistant prostate cancer (mCRPC).
This initiative prioritizes activities that address new mechanisms of action, such as EZH2 inhibition, and the critical unmet need for innovative therapies beyond traditional chemotherapy.
Grants ranging from $75,000 to $250,000 are available, with around $500,000 allocated in total for the call. Projects may receive funding for up to two years and must be completed within this timeframe. Proposals should come from medical schools, healthcare institutions, professional societies, medical education companies, and similar organizations in the US or Europe, and formal incorporation is required to receive funding.
Applicants should design initiatives that enhance healthcare professional awareness of novel mCRPC therapies, including combination strategies and current clinical trials. Suitable formats include conference symposia, webinars, multimedia resources such as videos and podcasts, articles, infographics, and more—each intended to strengthen understanding and improve patient care.
The geographic scope prioritizes projects in the United States and Europe, although proposals with a global reach are encouraged. Applicant organizations must be based in either the United States or Europe. Eligible applicants include medical, dental, nursing, allied health, and pharmacy professional schools, as well as healthcare institutions, professional organizations, medical societies, and medical education companies. Other entities with a mission tied to healthcare professional education or healthcare improvement are also welcome to apply.
Only organizations may apply; individual applicants or independent medical practice groups are not eligible. Where multiple departments or institutions are involved, each must have a relevant role, with the requesting organization serving as the lead. The project or program lead, or their authorized designee, must be an employee or contractor of the requesting organization. It is also essential that the requesting organization can legally receive award funding directly from Pfizer Inc., and applicants are strongly advised to confirm this with their institutions before submission.
Materials must be submitted via Pfizer’s online portal, adhering to formatting and submission guidelines provided. This grant is a valuable opportunity to lead educational advancement in oncology, ensuring that medical professionals are equipped with the latest insights and tools to improve outcomes for patients with advanced prostate cancer.
